Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2895203 | 0.78 | — | — | |
| SCHEMBL643186 | 0.77 | KDM4E (0.40) | — | |
| Hydrochloric Acid SCHEMBL4180932 | 0.76 | KDM4E (0.42) | — | |
| SCHEMBL1997009 | 0.74 | CYP3A4 (0.33) | — | |
| SCHEMBL508699 | 0.74 | CYP26A1 (0.31) | — | |
| SCHEMBL3662584 | 0.72 | HCAR3 (0.40) | — | |
| SCHEMBL2893466 | 0.70 | AR (0.33) | — | |
| SCHEMBL6474878 | 0.70 | ESR1 (0.32) | — | |
| SCHEMBL6474120 | 0.70 | — | — | |
| SCHEMBL1008603 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233969-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-01-12 | — | — | US | disclosed |
| US-20150105400-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150104483-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20140350250-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-20140350249-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-11-27 | — | — | US | disclosed |
| US-8835631-B2 | Therapeutic agent for cerebral infarction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-09-16 | — | — | US | disclosed |
| EP-2225238-B1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INT (DE) | 2014-09-03 | — | — | EP | disclosed |
| US-8552205-B2 | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3-carboxylic acid amides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2154135-B1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-02-27 | — | — | EP | disclosed |
| EP-2532658-A1 | Therapeutic agent for cerebral infarction | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-09-15 | — | — | US | disclosed |
| US-20100179157-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2154135-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224188-A1 | DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES | HPGDS, COL14A1, ARG1 | SYK 678/4885 |
| US-20150105400-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1B, IL1A | SYK 2502/4885 |
| US-20100179157-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | SYK 2435/4885 |
| US-20140350249-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | SYK 2435/4885 |
| US-20140350250-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | SYK 2435/4885 |
| US-20150104483-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | CCL2, IL1A, IL6 | SYK 2435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.